Rift Valley Fever and a New Paradigm of Research and Development for Zoonotic Disease Control

Osman Dar, Sabrina McIntyre, Sue Hogarth, and David Heymann

Although Rift Valley fever is a disease that, through its wider societal effects, disproportionately affects vulnerable communities with poor resilience to economic and environmental challenge, Rift Valley fever virus has since its discovery in 1931 been neglected by major global donors and disease control programs. We describe recent outbreaks affecting humans and animals and discuss the serious socio-economic effects on the communities affected and the slow pace of development of new vaccines. We also discuss the mixed global response, which has largely been fueled by the classification of the virus as a potential bioterrorism agent and its potential to migrate beyond its traditional eastern African boundaries. We argue for a refocus of strategy with increased global collaboration and a greater sense of urgency and investment that focuses on an equity-based approach in which funding and research are prioritized by need, inspired by principles of equity and social justice.

Since Rift Valley fever virus (RVFV) was first identified in 1931, after an investigation of an epizootic among sheep on a farm in the Great Rift Valley of Kenya, the understanding of this zoonotic disease has grown considerably (1). With the rapid progress of molecular biology and genetic techniques in recent years, studies of prevailing circulating variants of RVFV have pointed to a recent common ancestor that existed during 1880–1890. This finding lends weight to the predominant hypothesis on the origins of human outbreaks of Rift Valley fever, which suggests that the development of industrialized agriculture systems and the introduction of highly susceptible European breeds of livestock into East Africa during the colonial era led to amplification of the virus in animal and arthropod vectors and may have been responsible for the establishment of the disease (2).

Recent Outbreaks

The potential of RVFV to migrate was established after large outbreaks of RVF occurred among animals and humans in Egypt in 1977, in other geographic zones of Africa, and then outside the African continent in Saudi Arabia and Yemen in 2000 (3,4). The Figure illustrates how the disease has traveled away from its original identified location in humans and animals.

The Table further demonstrates the spread of the disease; 7 of 9 major outbreaks in the past 15 years resulted in human cases outside the Rift Valley region in East Africa. The Table also highlights the difficulty of developing adequate surveillance systems and therefore the difficulty...
of accurately estimating morbidity and mortality rates for human populations in resource-poor settings. In the 5 outbreaks for which estimated numbers of human cases have been published, ≈339,000 infections are believed to have occurred. In the 4 outbreaks for which estimated and reported cases are documented, numbers of estimated cases are 78× higher than numbers of reported cases (Table). This difference between estimated and known numbers of cases highlights the inherent complexity of managing outbreaks, monitoring their spread, and mitigating their effects.

**Socioeconomic Effects**

There is a paucity of studies that have examined the socioeconomic effects of past outbreaks of RVFV, which reflects a lack of research focus on the broader social effects of the disease. One study that did examine the socioeconomic effects of the 2006/2007 RVFV outbreak in Kenya highlighted the concern that the outbreak had tended to disproportionately affect impoverished pastoralist communities, with those in the North Eastern Province of Kenya being hardest hit (25,26). The lack of understanding of the epidemiology and pathophysiology of RVFV, poor compliance with international health and safety standards by animal exporters, and the limited options for prevention and treatment have periodically led to summary bans of imports of livestock from disease-endemic areas.

The ban of livestock imports to the Middle East from East Africa, instituted after the 1997/1998 RVFV outbreak in Kenya and Somalia, particularly affected the export trade out of Somalia. The ban was variably enforced by several Middle Eastern countries but most notably by Saudi Arabia, which imports large numbers of ruminants for the annual Haj pilgrimage. In 1997, the year before the onset of the ban, 2.8 million live animals were exported from the Somaliland port of Berbera, making it the single biggest exporting port for ruminants in the world that year. With the livestock trade accounting for 65% of gross domestic product in Somaliland, the export ban had a devastating effect on a region already suffering in the grip of a protracted civil war (27). Estimated losses from export sales out of Somaliland alone for the first 16 months of the ban from February 1998 to May 1999 totaled $109 million (28). By the time the ban on animal imports was lifted by Saudi Arabia in 2009, this drought- and war-affected region of East Africa had already endured many years of lost income because of prevailing fears concerning RVFV.

---

**Table. Major Rift Valley fever outbreaks and reported cases among humans, 1997–2010*\(^\d\)**

<table>
<thead>
<tr>
<th>Outbreak dates</th>
<th>Geographic distribution</th>
<th>Estimated no. cases</th>
<th>No. cases reported</th>
<th>No. deaths confirmed</th>
<th>Precipitation</th>
<th>Control measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>1997 Dec–1998 Jan</td>
<td>Kenya, Somalia, Tanzania</td>
<td>89,000</td>
<td>No documented reports</td>
<td>478</td>
<td>Heavy rainfall and flooding</td>
<td>Active surveillance; safety education; distribution of masks, gloves; slaughterhouse monitoring</td>
</tr>
<tr>
<td>1998 Sep–Dec</td>
<td>Mauritania</td>
<td>No documented estimates</td>
<td>300–400</td>
<td>6</td>
<td>Heavy rainfall</td>
<td>Active surveillance; public awareness/education; mosquito control; animal movement control</td>
</tr>
<tr>
<td>2000 Aug–2001 Sep</td>
<td>Saudi Arabia, Yemen</td>
<td>20,000†</td>
<td>886</td>
<td>123</td>
<td>Rainfall; virus introduction</td>
<td>Active surveillance; public awareness/education; mosquito control; animal movement control</td>
</tr>
<tr>
<td>2006 Nov–2007 Mar</td>
<td>Kenya, Somalia, Tanzania</td>
<td>75,000</td>
<td>700</td>
<td>158</td>
<td>Heavy rainfall and flooding</td>
<td>Active surveillance; public awareness/education; mosquito control; ban on livestock slaughter; closure of livestock market; vaccination Jan 2007</td>
</tr>
<tr>
<td>2007 Sep–2008 Jan</td>
<td>Sudan</td>
<td>75,000</td>
<td>747</td>
<td>230</td>
<td>Heavy rainfall and flooding</td>
<td>Active surveillance; public awareness/education; targeted vaccination; ban of livestock imports by Saudi Arabia and Egypt</td>
</tr>
<tr>
<td>2008 Jan–Jun</td>
<td>Madagascar</td>
<td>10,000</td>
<td>476</td>
<td>19</td>
<td>Heavy rainfall</td>
<td>Active surveillance; public awareness; mosquito control; animal movement control</td>
</tr>
<tr>
<td>2008 Oct–2009 May</td>
<td>Madagascar</td>
<td>No documented estimates</td>
<td>236</td>
<td>7</td>
<td>Heavy rainfall</td>
<td>Active surveillance; public awareness; mosquito control; animal movement control</td>
</tr>
<tr>
<td>2010 Feb–2010 May</td>
<td>South Africa</td>
<td>No documented estimates</td>
<td>242</td>
<td>26</td>
<td>Sustained heavy rains</td>
<td>Public awareness/education; mosquito control</td>
</tr>
<tr>
<td>2010 Sep–2010 Dec</td>
<td>Mauritania</td>
<td>No documented estimates</td>
<td>63</td>
<td>13</td>
<td>Heavy rainfall</td>
<td>Public awareness; mosquito control; animal movement control</td>
</tr>
</tbody>
</table>

*Sources: (6–24). FAO, Food and Agriculture Organization of the United Nations. †Data available for Jizan region only.
Vaccine Development and Production

The slow pace of development of new vaccines (online Technical Appendix; wwwnc.cdc.gov/EID/article/19/2/12-0941-Techapp1.pdf) and diagnostic kits for RVFV and the limited supplies and relatively high cost of those currently available mean that there is a chronic worldwide shortage and lack of availability in areas where they are most needed. To address these problems, a “pull” strategy has been suggested by the Food and Agriculture Organization of the United Nations for the development of new RVFV vaccines. In this model, governments commit themselves of the United Nations for the development of new RVFV vaccines. In this model, governments commit themselves to buy, at an agreed-upon price, whichever vaccine meets predefined requirements, thus giving an incentive to pharmaceutical companies to pursue the development of the most promising vaccine candidate. However, this strategy does not seem to be having much effect in the short term; the current financial crisis is limiting the purchasing power of national governments (29).

Before modern safety standards were instituted in laboratories, RVFV was regularly transmitted between laboratory staff; 47 cases were documented worldwide (30,31). International regulations for working with the live virus, and particularly for the production of vaccine and diagnostic test kits, typically require biosafety level 3 (BSL-3) laboratory facilities as a minimum and enhanced BSL-3 Ag/ABSL-3 (with many of the features of a BSL-4 laboratory) for working with live RVFV and loose-housed animals (30).

Fortunately, with the advent of recombinant genetic technology and the development of reverse transcription PCR techniques obviating the need to handle and store live virus, new vaccines and diagnostic tests in development can now be produced in laboratories of lower BSL (29,32). However, for the standard techniques that do involve storage and handling of live virus, because no reported laboratory infections have occurred since modern standard infection control procedures were introduced in the early 1980s (33), the case could be made for lowering currently prescribed BSL requirements. If laboratory workers handling live virus in these settings are all vaccinated, the laboratories required could possibly be reduced to BSL-2 with controlled access in disease-endemic countries, and to BSL-2 with controlled access and additional enhancements for working with animals in non–disease-endemic countries. Such a change could lower global production costs of vaccines and diagnostic tests and increase their accessibility by communities most affected by RVFV.

Global Interest, Challenges, and Cooperation

Interest in RVFV and investment in its control were only substantially increased among the global health research and policy community after greater awareness of its potential to migrate beyond its traditional East African boundaries was noted. However, the recognition that much of the industrialized world has animals and arthropod vectors capable of transmitting the virus seems to have focused and accelerated efforts to develop improved tools for outbreak forecasting, monitoring, diagnosis, and prevention.

In more recent years, the classification of the virus as a potential bioterrorism/agroterrorism agent has also helped spur investment and activity, particularly in the area of vaccine development and diagnostics (34). Although this theoretical risk has contributed to increased funding over the past few decades, most notably from military sources such as the US Army Medical Research Institute of Infectious Diseases, this concern might also have acted as an impediment to the collaborative aspects of this high-quality work, with research being restricted to fewer, more expensive laboratories (35).

Growing restrictions stemming from biosecurity concerns now affect research activity across a range of infectious diseases and have most recently been highlighted by concerns over the publication of research into the production of genetically engineered variants of the influenza A subtype H5N1 virus (36). Limiting the dissemination of such research findings could, in any case, curtail technology transfer crucial to studying viruses such as RVFV and could theoretically cause expert technical knowledge and skills to be less accessible. This possibility not only has the potential to delay progress in developing new treatments and vaccines but could also increase their costs by limiting where they could be produced, resulting in decreased production capacity and competition.

Increased sales costs of vaccines have a variety of negative consequences; in particular, this increase could put at risk well-established mechanisms of international cooperation in global infectious disease surveillance. This risk was dramatically highlighted in 2006 and 2007 when Indonesia refused to share samples of influenza subtype H5N1 isolates with the World Health Organization. The event caused a risk to global health and occurred in direct protest to the inequitable sharing of virus samples and vaccine development technology (37).

Despite some of these challenges, some positive developments have occurred in global collaborative efforts for controlling zoonotic diseases, including RVFV. These include initiatives like the One Health (38) approach of integrating animal and human health challenges and the closer integration of multilateral agencies such as the World Organisation for Animal Health, the Food and Agriculture Organization of the United Nations, and the World Health Organization. These efforts have already resulted in improved outbreak forecasting and surveillance of RVFV in humans and animals, facilitated by the development of initiatives such as the Global Early Warning

Rift Valley Fever Control
be answered conclusively, exploring the case for lowering current BSL requirements of laboratories and production facilities could be 1 method of mitigating these costs.

A greater sense of urgency and investment is required for controlling, better managing, and preventing future large-scale outbreaks of RVFV. Future long-term success lies in building on global collaborative initiatives, the closer integration of multilateral agencies, and a wider participation from livestock-importing countries and emerging economies that are investing in RVFV-endemic countries. A worldwide strategy, both in tune with and inspired by principles of equity and social justice, could ultimately deliver the best outcomes in combating this neglected tropical disease.

Dr Dar is a consultant in communicable disease control at the London School of Hygiene and Tropical Medicine and at the UK Health Protection Agency. He is also an honorary research fellow at the Chatham House Centre on Global Health Security. His research interests focus on global health, especially in low-income and conflict settings.

References

12. Al-Hazmi M, Ayoola EA, Abdurahman M, Banzal S, Ashraf J, El-
Rift Valley Fever and a New Paradigm of Research and Development for Zoonotic Disease Control

Technical Appendix

Vaccine Development

The first major breakthrough in efforts to combat Rift Valley fever (RVF) in animals occurred with the development of the live-attenuated Smithburn vaccine in the late 1940s. Although it was effective in inducing long-term immunity in animals, the vaccine unfortunately retains some virulence and is teratogenic, causing abortions in ewes, cows, and goats. This characteristic and the associated fears of inadvertently spreading RVF virus through needle transmission in animals during an outbreak has led to its use being restricted to nonpregnant animals preceding an imminent outbreak. A later inactivated-virus vaccine developed in the 1960s, although it did not have the same deleterious side-effect profile as the Smithburn strain, remains prohibitively expensive to prepare and requires 3 annually spaced inoculations to provide adequate immunity. Therefore, it is logistically complicated to deliver in low-income settings.

Several newer candidate vaccines have been in development since the 1970s, most notably the live attenuated strains MP-12 and clone 13 and, more recently, the R566 strain. The slow pace of their development, a process that has continued over 3 decades, highlights the relative lack of investment and the constrained nature of the research into this restricted pathogen. A positive development in this regard is the recent introduction of clone 13 for use in South Africa after studies demonstrated that the vaccine does not, seemingly, retain any of the residual pathogenicity or teratogenicity of the Smithburn vaccine.

Although an inactivated human vaccine strain, TSI-GSD-200, is available for use in limited quantities for military and laboratory staff, no vaccine is available for routine, generalized use in humans. Advances in technology and increased investment in the last decade
have meant that there is now a promising array of candidates for development, including recombinant vaccines, DNA based vaccines, and viruslike-particle vaccines. However, because relatively few laboratories and organizations have the facilities and skills to develop these vaccines, prioritizing their development over other more lucrative infections and vaccines remains problematic (1–3).

References

   http://dx.doi.org/10.1002/path.1700340418

   http://www.fao.org/docrep/014/i2310e/i2310e00.pdf